|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 1** Comparison of blood pressures, proteinuria and biochemical parameters between bevacizumab-treated pregnant rats and the control group. | | | | |
|  | | **Control Group**  **(n=8)** | **Bevacizumab Group (n=8)** | ***P* value** |
| Blood VEGF (pg/ml) | | 28.84±13.83 | 15.31±17,62 | **0.038** |
| Blood Sflt-1 (pg/ml) | | 108.11±26.50 | 168.47±59,87 | **0.015** |
| AST (U/L) | | 146.87±29,31 | 162.25±22.48 | 0.382 |
| ALT (U/L) | | 76.75±22.46 | 83.87±10.92 | 0.328 |
| BUN (mg/dl) | | 18.75±4.92 | 21.00±3,77 | 0.382 |
| Creatinine (mg/dl) | | 0.31±0.04 | 0.36±0.06 | 0.105 |
| Systolic blood pressure (mm Hg) | D0 | 120.87±6.89a | 126.25±6.94a | 0.130 |
| D20 | 120.62±11.09 | 132.37±14.16 | **0.050** |
| Diastolic blood pressure (mm Hg) | D0 | 78.62±5.04a | 83.37±6.69a | 0.195 |
| D20 | 78.00±3.81 | 84.75±7.62 | **0.046** |
| Proteinuria | D0 | 0.13±0.23a | 0.13±0.23b | 1.000 |
| D20 | 0.50±0.46 | 0.88±0.64 | 0.084 |

VEGF, vascular endothelial growth factor; Sflt-1, soluble fms-like tyrosine kinase 1, AST, aspartate aminotransferase, ALT, alanine transaminase, BUN, blood urea nitrogen. Mann-Whitney U test and Wilcoxon Signed Rank Tests were used for analysis. Data are presented as mean ± SD.

Boldface data indicates statistical significance (*p*<0.05).

a *p* ˃0.05, D0 vs. D20, b *p* =0.026, D0 vs. D20

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2** Comparison of fetal-maternal weight, histopathology and immunohistochemical results between bevacizumab-treated pregnant rats and the control group. | | | | |
|  | | **Control Group**  **(n=8)** | **Bevacizumab Group**  **(n=8)** | ***P* value** |
| Maternal weight (gr) | D0 | 213.38±6.93a | 213.50±5.71a | 0.959 |
| D20 | 242.50±7.65 | 240.25±10.36 | 0.878 |
| Maternal weight gain (gr) (D20-D0) | | 29.13±4.73 | 26.75±7.30 | 0.505 |
| Number of pups per litter | | 7.5±0.92 | 7.37±0.74 | 0.878 |
| Mean fetal weight (gr) | | 2.19±0.19 | 2.00±0.17 | 0.274 |
| Placental VEGF | | 6.31±4.54 | 5.55±3.64 | 0.328 |
| Placental Sflt-1 | | 5.62±4.14 | 8.12±4.82 | **0.050** |
| Placental CD31 | | 85.31±5.96 | 81.93±4.55 | 0.328 |
| Placental CD105 | | 83.81±6.48 | 80.56±5.80 | 0.234 |
| Glomerular endotheliosis | | 1.75±0.71 | 1.88±0.84 | 0.798 |

VEGF, vascular endothelial growth factor; Sflt-1, soluble fms-like tyrosine kinase 1. Mann-Whitney U test and Wilcoxon Signed Rank Tests were used for analysis. Data are presented as mean ± SD.

Boldface data indicates statistical significance (*p*<0.05).

a *p* =0.012, D0 vs. D20